Cyprotex are proud to announce the introduction of a new and comprehensive bioanalytical development and validation service. By offering this service, Cyprotex are greatly enhancing their current bioanalytical operation, allowing expansion of their Cloe® Select portfolio of later stage services. Studies plans for this service will be based on current regulatory guidance documentation for bioanalytical method validation.
Cyprotex have invested heavily in building up their bioanalytical facilities with the introduction of a state of the art Applied Biosystems Sciex QTRAP® 5500 LC-MS/MS and the recruitment of two senior bioanalytical scientists with a wealth experience and expertise in this area. The QTRAP® 5500 LC-MS/MS is one of the most sensitive ion trap and triple quadrupole instruments in the industry. Access to this technology will give our customers a superior bioanalytical service with exceptional quantitative and qualitative potential.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the launch of the service. "Reliable and robust bioanalytical methods are critical in the preclinical development process. Cyprotex can now offer a comprehensive bioanalytical method development and validation service which will be of particular interest to our Cloe® Select customers. Our clients will benefit from the very latest in bioanalytical technology with access to our QTRAP® 5500 LC-MS/MS.’